AICAR Benefits

AICAR Benefits from Direct Peptides United Kingdom

AICAR, short for 5-aminoimidazole-4-carboxamide ribonucleoside, is a naturally occurring substance that plays a significant role in energy balance and various metabolic pathways. It’s an allosteric activator of AMP-activated protein kinase (AMPK), a protein involved in cellular energy homeostasis. In the athletic world, AICA Ribonucleotide has been noted for its potential to improve athletic performance, although it’s considered a prohibited substance [1]. It’s also used widely in research due to its ability to modulate role of AMPK signalling especially surrounding the improvement of endurance and performance in sports.

The History of AICAR Benefits United Kingdom

In the medical world, AICAR has been used to restrict ischemia or the tissues’ blood supply. In early studies in the 1980s, it played an important role in preserving the heart’s blood flow. AICAR benefits has also shown promise when it comes to treating diabetes and glucose metabolism because of its capability of increasing the tissues’ metabolic ability, which it does by modifying the muscle’s composition.

How AICAR Works United Kingdom

United Kingdom Clinical studies have shown when AICAR triggers AMPK, it leads to the skeletal muscle cells up take in glucose. In the independent experiments conducted by the Salk Institute and Howard Hughes Medical Centre, mouse models given the AICAR peptide were able to run by an increase of 44% without needing to train. It’s not surprising that when athletes heard about this compound, they began to use it without fearing testing or regulation up until 2011 when the world anti doping agency decided to prohibit synthetic amp activated protein kinase for human use.

Check out AICAR peptides from Direct Peptides.

The dosages for AICAR for research purposes can differ depending on the physique of the subject. It is important to research the recommended dosage of any peptide before utilising it in your research to optimise it’s beneficial effects.

Shop Peptide Supplies from Direct Peptides for all your reconstitution requirements.

Studies on AICAR Benefits United Kingdom

This peptide is known for its incredible effect on increasing endurance levels and burning fat. Many United Kingdom studies show this peptide often researched on rodent subjects results showed the peptide to induce metabolic genes. It’s capable of improving one’s running endurance significantly. This peptide can do enhance endurance by transforming fast-twitch muscle fibres into becoming a fat-burning, more energy-efficient, slow-twitch fibres.

AICAR benefits, a ribonucleoside, has shown the possibility of being a potential treatment of various forms of Leukaemia. United Kingdom Studies have demonstrated that it can induce apoptosis, or programmed cell death, in chronic lymphocytic leukaemia (CLL) cells, providing an alternative therapeutic option for patients with impaired p53 function [2]. Moreover, AICAR has been found to suppress cell proliferation and enhance sensitivity of other leukaemia types to treatment, suggesting its possible role in targeted therapy.

Furthermore, the peptide has shown potential in the treatment and management of diabetes. United Kingdom Studies suggest that long-term administration  can improve glucose tolerance and lipid profile, potentially helping to manage symptoms of type 2 diabetes [3].

Moreover, AICAR benefits have found to increase insulin-stimulated glucose uptake and reduce hepatic glucose output. This indicates its therapeutic potential for insulin resistance and blood glucose regulation, highlighting its importance in managing metabolic disorders.

The products mentioned in this posts intended for research and medical purposes only, to be only used by trained professionals.

References:

[1] Dora Višnjić, Hrvoje Lalić, Vilma Dembitz, Barbara Tomić, and Tomislav Smoljo (2021) AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review – Cells, 2021 May 4, Volume 10 (Issue 5), Page 1095.

[2] Antonio F Santidrián, Diana M González-Gironès, Daniel Iglesias-Serret, Llorenç Coll-Mulet, et al (2010) AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells – Blood, 2010 Oct 21, Volume 116 (Issue 16), Pages 3023-32.

[3] Rasmus Pold, Lasse S Jensen, Niels Jessen, Esben S Buhl, Ole Schmitz, Allan Flyvbjerg, et al (2005) Long-term AICAR administration and exercise prevents diabetes in ZDF rats – Diabetes, 2005 Apr, Volume 54 (Issue 4), Pages 928-34.